Renvela

Renvela. It is a phosphate binder medication used to control hyperphosphatemia in patients with chronic kidney disease who are on dialysis. The drug is the carbonate salt form of sevelamer, a non-absorbed polymer, and works by binding dietary phosphate in the gastrointestinal tract. It is marketed by Genzyme, a subsidiary of Sanofi, and is available in both tablet and powder for oral suspension formulations.

Medical uses

Renvela is indicated for the control of serum phosphorus in patients with chronic kidney disease on hemodialysis or peritoneal dialysis. Its use is critical in managing the mineral and bone disorder associated with chronic kidney disease, helping to prevent complications like vascular calcification and secondary hyperparathyroidism. Clinical studies, such as those published in the New England Journal of Medicine, have demonstrated its efficacy in lowering phosphate levels without adding calcium or metal load to the body. It is often compared to other binders like calcium acetate, lanthanum carbonate, and ferric citrate in treatment guidelines from organizations like the National Kidney Foundation.

Adverse effects

The most common adverse reactions involve the gastrointestinal tract and include nausea, vomiting, diarrhea, dyspepsia, and abdominal pain. Serious complications, though rare, can include intestinal obstruction, bowel perforation, and fecal impaction, particularly in patients with pre-existing gastrointestinal disorders. Drug interactions are possible, as Renvela can bind to and decrease the absorption of concomitantly administered oral medications, such as levothyroxine and ciprofloxacin, necessitating careful dosing schedules. Post-marketing surveillance by the U.S. Food and Drug Administration has also noted reports of hypersensitivity reactions including rash and pruritus.

Pharmacology

Sevelamer carbonate is a hydrophilic, cross-linked polymer that is not absorbed from the gastrointestinal tract. It contains multiple amine groups separated by one carbon from the polymer backbone, which become partially protonated in the acidic environment of the stomach, binding negatively charged phosphate ions through ionic and hydrogen bonding. The bound phosphate is then excreted in the feces, thereby reducing its absorption. Unlike metal-based phosphate binders, it does not contain aluminum, calcium, or magnesium, eliminating risks associated with systemic accumulation of these elements. Its mechanism is purely local within the gastrointestinal tract.

History

The hydrochloride salt, sevelamer hydrochloride, was first approved by the U.S. Food and Drug Administration in 1998 under the brand name Renagel, developed by GelTex Pharmaceuticals. The carbonate salt, Renvela, was later developed to offer a buffered alternative that did not contribute to metabolic acidosis, receiving FDA approval in 2007. The development was part of a broader effort to find effective non-calcium, non-metal binders, driven by research into the dangers of vascular calcification highlighted by studies from the Cochrane Collaboration. The intellectual property and marketing rights were subsequently acquired by Genzyme, which expanded its global availability.

Society and culture

Renvela is a significant product in the nephrology pharmaceutical market and has been the subject of cost-effectiveness analyses within healthcare systems like the National Health Service in the United Kingdom. Its availability has been impacted by patent disputes and generic competition, involving companies like Mylan and Watson Laboratories. The drug is listed on the World Health Organization Model List of Essential Medicines, underscoring its importance in managing a global health burden. Patient assistance programs have been established by Sanofi to support access, and its use is frequently discussed in patient advocacy forums such as the American Association of Kidney Patients. Category:Drugs